Business
ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections
Company Offers Assistance with Coronavirus Global Health Initiatives Company Receives Notification from USPTO Regarding Extension to Its Issued Patents
About this update from Adma Biologics Inc
[{"type":"text","content":"Company Offers Assistance with Coronavirus Global Health Initiatives\n Company Receives Notification from USPTO Regarding Extension to Its Issued Patents Related and Applied to Composition and Therapeutic Use of Immune Globulin; Extension Expected to Publish in 1H2020 RAMSEY, N.J. and BOCA RATON, Fla., March 03, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™. ADMA is the exclusive owner of intellectual property encompassing certain immunotherapeutic, immunoglobulin (IG & IVIG) compositions for the prevention and treatment of a wide variety of respiratory infections, including certain strains of coronavirus. “We are pleased to announce the continued enhancement and strengthening of our patent estate focused on plasma derived immune globulins for the treatment and prevention of respiratory viral infections,” said Adam Grossman, President and Chief Executive Officer of ADMA. “This most recent notice of patent allowance by the USPTO is very timely in the midst of the reported global coronavirus epidemic. We are pleased to be one of the leading plasma products companies focused on developing novel and patentable approaches for the use of immune globulins to treat and prevent respiratory infections and illness caused by viral pathogens.” ADMA’s commercially available immune globulin products, intellectual property, and the Company’s deep understanding of specialty antibody-rich immune globulins focused on respiratory pathogens provide ADMA a unique position to collaborate with government agencies, vaccine manufacturers and other parties in the fight to combat emerging infectious disease including the global coronavirus epidemic. ADMA’s issued patents include proprietary immunotherapeutic compositions comprised of plasma derived immune globulin which has higher than normal titers for respiratory pathogens ...